Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 21, 2021

With $39B buyout deal closing, Alexion now part of AstraZeneca

PHOTO | Contributed Alexion, AstraZeneca Rare Disease's research facility at 100 College St. in New Haven.

New Haven-born Alexion Pharmaceuticals, whose blockbuster blood-disorder drug Soliris made it one of the Elm City’s biggest biotech success stories a decade ago, is now officially the rare disease arm of pharma giant AstraZeneca.

UK-based AstraZeneca said it wrapped up its $39 billion acquisition of Alexion on Wednesday, a week after clearing its final hurdle with a green light from UK regulators.

First announced last December, the acquisition has been billed by industry observers as the biggest pharma deal of 2020.

“Today we welcome our new colleagues from Alexion to AstraZeneca and begin a new chapter that will augment our growth for years to come,” AstraZeneca CEO Pascal Soriot said in a statement. 

With the closing, AstraZeneca Chief Financial Officer Marc Dunoyer replaces Ludwig Hantson as CEO, while Alexion CFO Aradhana Sarin takes over as CFO for AstraZeneca.

Alexion will be renamed “Alexion, AstraZeneca Rare Disease” and will stay in Boston, where the company moved its corporate headquarters in 2018.

AstraZeneca has previously said it expects to also have a “continued presence” in the Elm City, where it now employs more than 500 at its 100 College St. research facility.

The companies have not offered details about the size of that presence, but have said that all current site plans “will remain unchanged” through the end of 2021.

Contact Natalie Missakian at

Sign up for Enews


Order a PDF